GCP
GILD icon

Gill Capital Partners’s Gilead Sciences GILD Stock Holding History

Gill Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7K Hold
338
– – 0.01% 291
2026
Q1 		$47.1K Buy
+338
New +$47.3K 0.01% 267

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gill Capital Partners's GILD Position: Q2 2026 in Review

Gill Capital Partners held its Gilead Sciences (GILD) position steady in Q2 2026 at 338 shares worth $42.7K. The position accounts for 0.01% of the portfolio, ranked #291.

Gill Capital Partners first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $47.1K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Gill Capital Partners held 338 shares of Gilead Sciences worth $42.7K as of Q2 2026.
  • Gill Capital Partners left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.01% of Gill Capital Partners's portfolio in Q2 2026, its #291 holding.
  • Gill Capital Partners first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Gill Capital Partners's Gilead Sciences position peaked at $47.1K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.